France's Pasteur Institute said on Monday it was ending development of a Covid-19 vaccine with US pharmaceutical company Merck after clinical trial results proved disappointing, reports FRANCE 24.
The partners announced a tie-up last May to develop a jab based on an existing measles vaccine, which was put into Phase 1 clinical trials in August.
"In these first human trials, the prospective vaccine was well tolerated but produced immune responses that were inferior to those observed in people who had recovered naturally and to those observed in the authorised vaccines," a statement from Pasteur Institute said.
The announcement is a further blow for hopes of a French-led vaccine following recent news that leading national pharmaceutical company Sanofi is also struggling to bring its vaccine candidate to market.
Sanofi announced in December that its jab would be ready by the end of 2021 at best, and the group is now being encouraged by the government to help produce rival vaccines that have already been authorised for use in Europe.
Read more of this report from FRANCE 24.
See Mediapart's report on the Sanofi vaccine here.